Inovio Pharmaceuticals reports developments in DNA medicines for HPV-related diseases, cancer and infectious diseases. Its updates center on INO-3107, a DNA immunotherapy candidate for recurrent respiratory papillomatosis, including clinical data, scientific publications, FDA review milestones and presentations at medical and biotechnology conferences.
Company news also includes quarterly and annual financial results, business updates, research on DNA-encoded monoclonal antibodies and DNA-encoded protein technology, collaboration activity and capital-structure actions involving common stock, warrants and at-the-market financing programs.
Inovio (Nasdaq: INO) announced a proposed underwritten public offering of common stock and accompanying warrants to purchase common stock, or pre-funded warrants in lieu of common stock. Inovio intends to grant the underwriter a 30-day option to buy up to an additional 15% of the offered shares and/or accompanying warrants on the same terms.
All securities in the proposed offering would be sold by Inovio. The transaction is subject to market conditions, with no assurance on completion, size, or terms. Piper Sandler is acting as sole manager. The securities are being offered under an effective shelf registration statement filed July 2, 2026 and declared effective July 10, 2026.
INOVIO (NASDAQ: INO) announced participation in upcoming scientific and investor conferences. Management will take part in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4 at 8:45 AM ET and present a poster at the World Orphan Drug Congress in Boston on June 11 from 12:00–12:10 PM ET.
A replay of the Jefferies investor event will be available for 90 days, and management will also hold one-on-one meetings with investors.
INOVIO (NASDAQ: INO) reported that partner ApolloBio announced positive topline results from a pivotal Phase 3 trial of VGX-3100 in cervical dysplasia patients. The study met its predefined primary efficacy endpoint and showed an overall favorable safety and tolerability profile, supporting a planned regulatory submission in China.
Under the ApolloBio agreement, INOVIO may receive up to $20 million in regulatory milestones, net of taxes, plus tiered royalties on annual net sales if VGX-3100 is approved and marketed in specified territories.
INOVIO (NASDAQ: INO) reported Q1 2026 results and pipeline updates. R&D expenses were $14.1M, G&A $7.9M and total operating expenses $21.9M, all lower year over year. Net loss was $19.7M, or $0.28 per share. Cash and investments were $37.7M, excluding $16.0M April offering proceeds.
The FDA is actively reviewing the BLA for INO-3107 for recurrent respiratory papillomatosis, with an accelerated approval target PDUFA date of October 30, 2026. INOVIO plans U.S. self-commercialization and expects current cash to fund operations into Q1 2027. The company also announced an INO-5412 GBM trial collaboration with Akeso.
INOVIO (NASDAQ:INO) will present posters at two upcoming scientific conferences in May 2026: the American Society of Gene and Cell Therapy (Boston) and the American Society of Clinical Oncology (Chicago). Presentations cover hemophilia A gene transfer and INO-3107 DNA immunotherapy for recurrent respiratory papillomatosis. Available abstracts will be posted on the company website after each presentation.
INOVIO (NASDAQ:INO) will release its first quarter 2026 financial results after market close on May 13, 2026. A live conference call and webcast will follow at 4:30 p.m. ET for a financial review and general business update, with a listen-only format and live Q&A.
The webcast will be archived and available for replay for 90 days at the company's investor events page.
INOVIO (Nasdaq: INO) priced an underwritten public offering of 12,500,000 common shares with accompanying Series A and Series B warrants at a combined public offering price of $1.40 per share and warrants, expected to close on or about April 6, 2026.
The company expects gross proceeds of approximately $17.5 million before discounts, and granted the underwriter a 30-day option to purchase up to 1,875,000 additional shares and warrants. Piper Sandler is sole manager.
INOVIO (NASDAQ: INO) announced a proposed underwritten public offering of common stock and accompanying Series A and Series B warrants (or pre-funded warrants) to purchase common stock.
The company said it will sell all securities offered, grant a 30-day underwriter option for up to 15% additional securities, and named Piper Sandler as sole manager. The offering is subject to market conditions and may not be completed.
INOVIO (NASDAQ: INO) will present at the World Federation of Hemophilia World Congress in Kuala Lumpur on April 22, 2026. The company will deliver a talk on DNA-Encoded Protein (DPROT) production of functional FVIII and a poster on non-viral DNA medicine FVIII expression in Hemophilia A mice.
Presentations are scheduled at 9:45 AM MYT (talk) and 10:45 AM MYT (poster). According to the company, abstracts will be posted on INOVIO's website after the presentations.
INOVIO (NASDAQ: INO) reported Q4 and full-year 2025 results and business updates, including a BLA acceptance for INO-3107 with a PDUFA target date of October 30, 2026. The FDA noted a potential issue on accelerated approval eligibility and agreed to meet. The company reported $58.5M cash and a projected runway into Q4 2026.
2025 financials: R&D $54.2M, G&A $32.7M, total operating expenses $86.9M, and a full-year net loss of $84.9M. INOVIO highlighted published clinical data and collaborations advancing its DNA medicine pipeline.